Glial-derived Neurotrophic Factor Gene Transfer for Parkinson's Disease: Anterograde Distribution of AAV2 Vectors in the Primate Brain

Overview

Journal Neurobiol Dis

Specialty Neurology

Date 2011 Oct 25

PMID 22019719

Citations 34

Authors

Adrian P Kells

John Forsayeth

Krystof S Bankiewicz

Affiliations

Soon will be listed here.

Abstract

Delivery of neurotrophic factors to treat neurodegenerative diseases has not been efficacious in clinical trials despite their known potency for promoting neuronal growth and survival. Direct gene delivery to the brain offers an approach for establishing sustained expression of neurotrophic factors but is dependent on accurate surgical procedures to target specific anatomical regions of the brain. Serotype-2 adeno-associated viral (AAV2) vectors have been investigated in multiple clinical studies for neurological diseases without adverse effects; however the absence of significant clinical efficacy after neurotrophic factor gene transfer has been largely attributed to insufficient coverage of the target region. Our pre-clinical development of AAV2-glial-derived neurotrophic factor (GDNF) for Parkinson's disease involved real-time image guided delivery and optimization of delivery techniques to maximize gene transfer in the putamen. We have demonstrated that AAV2 vectors are anterogradely transported in the primate brain with GDNF expression observed in the substantia nigra after putaminal delivery in both intact and nigrostriatal lesioned primates. Direct midbrain delivery of AAV2-GDNF resulted in extensive anterograde transport to multiple brain regions and significant weight loss.

Citing Articles

Emerging Gene Therapies for Alzheimer's and Parkinson's Diseases: An Overview of Clinical Trials and Promising Candidates.

Roberts W, Price S, Wu M, Parmar M Cureus. 2024; 16(8):e67037.

PMID: 39286667 PMC: 11405083. DOI: 10.7759/cureus.67037.

Recombinant Adeno-Associated Virus Vectors for Gene Therapy of the Central Nervous System: Delivery Routes and Clinical Aspects.

Slyk Z, Stachowiak N, Malecki M Biomedicines. 2024; 12(7).

PMID: 39062095 PMC: 11274884. DOI: 10.3390/biomedicines12071523.

From lab bench to hope: a review of gene therapies in clinical trials for Parkinson's disease and challenges.

Grote J, Patel N, Bates C, Parmar M Neurol Sci. 2024; 45(10):4699-4710.

PMID: 38795270 DOI: 10.1007/s10072-024-07599-1.

Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.

Heiss J, Ray-Chaudhury A, Kleiner D, Ehrlich D, Scott G, Edwards N Mov Disord. 2024; 39(8):1412-1417.

PMID: 38718138 PMC: 11341257. DOI: 10.1002/mds.29820.

Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system.

Campos L, Arokiaraj C, Chuapoco M, Chen X, Goeden N, Gradinaru V Curr Res Neurobiol. 2023; 4:100086.

PMID: 37397806 PMC: 10313870. DOI: 10.1016/j.crneur.2023.100086.

References

Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K . A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther. 2010; 18(9):1731-5. PMC: 2956925. DOI: 10.1038/mt.2010.135. View

Lang A, Gill S, Patel N, Lozano A, Nutt J, Penn R . Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006; 59(3):459-66. DOI: 10.1002/ana.20737. View

Hadaczek P, Kohutnicka M, Krauze M, Bringas J, Pivirotto P, Cunningham J . Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther. 2006; 17(3):291-302. DOI: 10.1089/hum.2006.17.291. View

Kirik D, Georgievska B, Bjorklund A . Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci. 2004; 7(2):105-10. DOI: 10.1038/nn1175. View

Johnston L, Eberling J, Pivirotto P, Hadaczek P, Federoff H, Forsayeth J . Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther. 2009; 20(5):497-510. PMC: 2767387. DOI: 10.1089/hum.2008.137. View

Kells A, Eberling J, Su X, Pivirotto P, Bringas J, Hadaczek P . Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci. 2010; 30(28):9567-77. PMC: 2914692. DOI: 10.1523/JNEUROSCI.0942-10.2010. View

Richardson R, Kells A, Rosenbluth K, Salegio E, Fiandaca M, Larson P . Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther. 2011; 19(6):1048-57. PMC: 3129792. DOI: 10.1038/mt.2011.11. View

Choi-Lundberg D, Lin Q, Schallert T, Crippens D, Davidson B, Chang Y . Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol. 1999; 154(2):261-75. DOI: 10.1006/exnr.1998.6887. View

Ciesielska A, Mittermeyer G, Hadaczek P, Kells A, Forsayeth J, Bankiewicz K . Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther. 2010; 19(5):922-7. PMC: 3098627. DOI: 10.1038/mt.2010.248. View

10.

Pascual A, Hidalgo-Figueroa M, Piruat J, Pintado C, Gomez-Diaz R, Lopez-Barneo J . Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci. 2008; 11(7):755-61. DOI: 10.1038/nn.2136. View

11.

Kaplitt M, Feigin A, Tang C, Fitzsimons H, Mattis P, Lawlor P . Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007; 369(9579):2097-105. DOI: 10.1016/S0140-6736(07)60982-9. View

12.

Nutt J, Burchiel K, Comella C, Jankovic J, Lang A, Laws Jr E . Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003; 60(1):69-73. DOI: 10.1212/wnl.60.1.69. View

13.

Choi-Lundberg D, Lin Q, Chang Y, Chiang Y, Hay C, Mohajeri H . Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science. 1997; 275(5301):838-41. DOI: 10.1126/science.275.5301.838. View

14.

Tomac A, Widenfalk J, Lin L, Kohno T, Ebendal T, Hoffer B . Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci U S A. 1995; 92(18):8274-8. PMC: 41139. DOI: 10.1073/pnas.92.18.8274. View

15.

LeWitt P, Rezai A, Leehey M, Ojemann S, Flaherty A, Eskandar E . AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011; 10(4):309-19. DOI: 10.1016/S1474-4422(11)70039-4. View

16.

Kordower J, Palfi S, Chen E, Ma S, Sendera T, Cochran E . Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. 1999; 46(3):419-24. DOI: 10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q. View

17.

Connor B, Kozlowski D, Schallert T, Tillerson J, Davidson B, Bohn M . Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 2000; 6(12):1936-51. DOI: 10.1038/sj.gt.3301033. View

18.

Hovland Jr D, Boyd R, Butt M, Engelhardt J, Moxness M, Ma M . Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol. 2007; 35(5):676-92. DOI: 10.1080/01926230701481899. View

19.

Christine C, Starr P, Larson P, Eberling J, Jagust W, Hawkins R . Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009; 73(20):1662-9. PMC: 2839805. DOI: 10.1212/WNL.0b013e3181c29356. View

20.

Marks Jr W, Bartus R, Siffert J, Davis C, Lozano A, Boulis N . Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010; 9(12):1164-1172. DOI: 10.1016/S1474-4422(10)70254-4. View